Introduction:
In recent years, calcitonin gene-related peptide (CGRP) recombinant protein has attracted much attention as a new type of biological drug. CGRP is a neuropeptide that is closely related to physiological processes such as pain conduction, neuro-vascular regulation, and inflammatory response regulation. CGRP abnormalities found in neurotransmitters and inflammatory mediators are closely related to the occurrence and progression of a variety of diseases. This article will give you a detailed introduction to the CGRP recombinant protein and its application prospects in the medical field.
Catalog Number: PA1000-704
1.Physiological function of CCRP.
Calcitonin gene-related peptide (CGRP) is a peptide molecule encoded by the Calca gene, which is mainly found in the central nervous system and peripheral nervous system. CGRP is involved in a variety of physiological and pathological processes by binding to its receptors. It plays an important role in pain conduction, neuro-vascular regulation, and inflammatory response regulation.
2.Association of CCRP with disease.
In recent years, studies have found that CGRP abnormalities are closely related to the occurrence and progression of a variety of diseases. For example, patients with conditions such as migraine, rheumatoid arthritis, pulmonary hypertension, and irritable bowel syndrome tend to have higher levels of CGRP. As a result, researchers are exploring new ways to regulate CGRP levels.
3.Preparation method of CCRP recombinant protein.
In order to study CGRP and explore its potential in ** diseases, researchers used recombinant DNA technology to prepare CGRP recombinant proteins. The protein was expressed by Escherichia coli or mammalian cells, and after purification and modification, a recombinant CGRP protein with high purity and stable activity was obtained.
4.Clinical application prospects of CCRP recombinant proteins.
With the deepening of the research on CGRP recombinant protein, its potential in clinical application has attracted more and more attention. At present, CGRP recombinant protein has been used in migraine prevention**. Clinical trial results have shown that CGRP recombinant protein can significantly reduce the frequency and intensity of migraine attacks, and *** less. Researchers are continuing to explore the potential of CGRP recombinant protein in other therapies.
Conclusion: As a new type of biological drug, calcitonin gene-related peptide (CGRP) recombinant protein has broad application prospects. By regulating the level of CGRP, it can regulate a variety of physiological processes such as pain conduction, neuro-vascular regulation, and inflammatory response, so it has shown great potential in multiple cases. With the in-depth study of CGRP recombinant protein, we have reason to believe that CGRP recombinant protein will bring new hope to the medical field.
References: 1 edvinsson l. cgrp receptor antagonists and antibodies against cgrp and its receptor in migraine treatment. br j clin pharmacol. 2015;80(2):193-199.
2. edvinsson l. the cgrp pathway in migraine as a viable target for therapies. headache. 2018;58 suppl 1:33-47.
3. durham pl. cgrp-receptor antagonists - a fresh approach to migraine therapy? n engl j med. 2017;376(7):680-681.
4. li n, et al. monoclonal antibodies for the treatment of calcitonin gene-related peptide-mediated conditions. expert opin biol ther. 2015;15(6):859-870.